New management team in Axelar AB

The Board of Axelar AB has appointed Vidar Wendel-Hansen as new Chief Executive Officer at the Annual Meeting on June 20th. Dr Wendel-Hansen holds an MD, PhD from Karolinska Institutet and has more than twenty years’ experience from the life science industry. Vidar has also worked as a clinical assessor at the Swedish Medical Products Agency. He has been responsible for clinical development within Axelar since September 2017.

Concomitantly, Anette Wärnmark Carr joins the new management team as Chief Scientific Officer.  She has been engaged in Axelar since 2015 with primary focus on drug formulation and related patent work. Anette has over 20 years’ experience of project management, both as Senior Scientist at Karolinska Institutet and in the pharmaceutical industry. She holds a MSE in Chemistry from the Royal Institute of Technology (KTH) and a PhD in Cell and Molecular Biology from the Karolinska Institutet.

“I am delighted to have the opportunity to collaborate with Dr Wärnmark Carr during the very interesting period that lies ahead for the company” says the new CEO. “I also want to thank my predecessor, Ms Ulrika Wennberg, for her efforts and important contribution during her tenure at Axelar.”

About Axelar AB

Axelar is a Swedish drug development company developing targeted oral anti-cancer therapies for indications where there are significant unmet medical needs. The company was founded based on research performed at Karolinska Institutet, Stockholm and the discovery of a group of compounds that target the IGF-1 receptor signaling pathway without affecting signaling from the closely related insulin receptor.

For additional information about Axelar, please visit

Go back